Psoriasis | Treatment Algorithms: Claims Data Analysis | Pediatric Psoriasis | US | 2023

Psoriasis is a chronic, inflammatory, autoimmune skin disease that can affect children, adolescents, and adults. Although adult psoriasis and pediatric psoriasis are similar, effective management of pediatric psoriasis is more challenging owing to the limited number of treatments approved for children. Only four biologics—Amgen’s Enbrel, Janssen’s Stelara, Eli Lilly’s Taltz, and Novartis’s Cosentyx—are approved to treat pediatric and adolescent patients with psoriasis. Although topical corticosteroids continue to be the mainstay of pediatric treatment, this class is expected to face competition from a recently approved nonsteroidal topical cream, Arcutis Biotherapeutics’ Zoryve, in patients 12 years or older. Additionally, the use of biologics is gradually increasing in pediatric patients, especially in the later lines, owing to the more-frequent and severe adverse events associated with long-term use of topical corticosteroids in children. Nevertheless, significant unmet need remains for efficacious therapies with better safety profiles for this psoriasis subpopulation.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed pediatric psoriasis patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed pediatric psoriasis patients?
• How have targeted therapies such as Cosentyx, Enbrel, Humira, Remicade, Stelara, Taltz, Tremfya, and Skyrizi and the novel nonsteroidal topical Zoryve been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of pediatric psoriasis patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of pediatric psoriasis patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Markets covered: United States

Key companies: AbbVie, Amgen, Arcutis, Astellas, Bausch Health, Eli Lilly, Janssen, Novartis.

Key drugs: Cosentyx, Elidel, Enbrel, Humira, Remicade, Skyrizi, Stelara, Taclonex, Taltz, Tremfya, Zoryve

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.